Complex Generics: Gottlieb Eyes FDA Policy Changes To Speed Approvals

US agency could reconsider requirement that instructions for use be same for branded and generic products, FDA Commissioner-nominee Scott Gottlieb suggests, while also leaving door open to statutory changes in Hatch-Waxman Act.